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A B S T R A C T
Tranexamic acid (TXA) is an antifibrinolytic drug, with the ability to inhibit lysine binding at plasminogen
receptors, used in adult trauma patients with on-going or at risk of significant haemorrhage. To understand the
pharmacokinetics and pharmacodynamics of this drug in variable age groups undergoing surgeries with high
blood loss, effective methods for determination of TXA in biological samples at sub-μgmL−1 are still required.
We describe herein the development and validation of a method based on ultra-high performance liquid chro-
matography coupled to triple quadrupole-tandem mass spectrometry to quantify TXA in human plasma. An
inexpensive, simple and efficient sample clean-up was implemented, not requiring matrix-matching calibration.
Sample preparation consisted in protein precipitation using acetonitrile containing 0.5% (v/v) formic acid,
followed by hydrophilic interaction based chromatographic separation, with elution in isocratic mode using a
combination of acetonitrile and water (75:25, v/v), with quantification of TXA based on selected reaction
monitoring. Good linearity was achieved (r2 > 0.997) for TXA concentrations ranging from 30 to 600 ngmL−1,
with LOD of 18 ngmL−1 in plasma. The developed method proved to be selective, sensitive, accurate
(96.4–105.7% of nominal values) and precise (RSD≤ 4.5%). TXA was found to be stable in plasma extracts
standing 24 h at room temperature (20 °C) or in the autosampler, and after three freeze-thawing cycles. Mean
recovery values of TXA spiked plasma samples were ≥91.9%. No significant matrix effects were observed. The
proposed methodology was successfully applied to the clinical study of plasma samples recovered during sco-
liosis surgery of pediatric patients pretreatment with TXA.
1. Introduction
Tranexamic acid [trans-4-(aminomethyl)cyclohexane-1-car-
boxylic acid] (TXA, Fig. 1) has been recently included in the World
Health Organization (WHO) core list of essential medicines for use in
adult trauma patients with on-going significant haemorrhage, or at
risk of significant haemorrhage within 8 h of injury [1]. Despite its
recognition as an important antifibrinolytic drug [2–5], there is a
lack of pharmacokinetic and pharmacodynamic data for TXA con-
cerning variable age groups undergoing surgeries with high blood
loss. Clinical trials performed so far suggest a wide variability in
response to TXA and, therefore, the optimum dose and administra-
tion schedules of TXA are still subject of research, aiming at a safe
inhibition of fibrinolysis in the perioperative period. Hence, effective
methods for determination of TXA in biological samples, including
detection at low levels, e.g. ng per milliliter levels, are of utmost
importance.
Several methods have been proposed for quantification of TXA
in biological fluids, including human plasma and serum [6]. Due to
the complexity of biological matrices, most of the techniques used
to quantify TXA require a careful sample pre-treatment to remove
potential interferences, namely proteins and branched-chain amino
T
acids. As TXA has a structural resemblance to amino acids, the
concomitant presence of these molecules in biological samples can
interfere during preparative separation procedures. In most cases, a
deproteinization step with acetonitrile is selected, after addition of
an appropriate internal standard (IS) whenever required.
The most commonly used methods for quantification of TXA as-
sociate reversed-phase HPLC to fluorescence [7–10] or UV [11–13]
detection. Since TXA does not possess in its chemical structure a
chromophore or fluorophore, exhibiting therefore a poor absorption at
220 nm, a derivatization step is required. MS detection, however, en-
ables straightforward analyte identification and a tendency to use this
technique has been observed in more recent reports [14–22]. Detection
limits ranging from 0.01 to 0.5 μgmL−1 in blood plasma were so far
attained using LC-MS/MS [14,16,18–20,22]. Although LC-MS/MS al-
lows increased sensitivity and the ability to measure down to the
ngmL−1 range in complex matrices such as plasma or serum, it still
requires attention and development due to issues concerning sample
treatment, matrix effects on ion suppression/enhancement, and studies
on analyte ionization efficiency.
In this context, the aim of this work was to develop and validate a
UHPLC-MS/MS method for the quantification of TXA in human plasma.
Minimal sample treatment was pursued for high-throughput applica-
tions, aiming also to reduce the manipulation of biological materials.
The proposed methodology was successfully applied to the clinical
study of samples recovered during scoliosis surgery of pediatric patients
dosed with TXA.
2. Material and methods
2.1. Chemicals
Tranexamic acid and 13C2,15N,trans-tranexamic acid (Fig. 1), used as
internal standard (TXA-IS), were purchased from Toronto Research
Chemicals Inc. (Toronto, ON, Canada), through LGC standards (Barce-
lona, Spain). Acetonitrile (LiChrosolv LC-MS grade) and formic acid
were acquired from Merck (Darmstadt, Germany). Ammonium bi-
carbonate (LC-MS grade) was acquired from Fluka (Buchs, Switzer-
land). Water from arium water purification system (resistivity> 18
MΩ cm, Sartorius, Göttingen, Germany) was used for the preparation of
all solutions. Two different mixtures of acetonitrile and water con-
taining 10mM NH4HCO3, pH 7.4 (A and B) were used for studying
mobile phase composition. Component A consisted of acetonitrile-
water-aqueous ammonium bicarbonate (pH 7.4; 100mM) (30:60:10, v/
v/v) whereas component B consisted of acetonitrile-water-aqueous
ammonium bicarbonate (pH 7.4; 100mM) (80:10:10, v/v/v). Prior to
use, both mobile phase components were filtered through 0.45 μm
Millipore (Billerica, MA) HVHP filters and degassed in an ultrasonic
bath for 15min.
2.2. Preparation of standard solutions
Stock solutions of TXA and TXA-IS were prepared in water at
1mgmL−1 and stored at −20 °C. Intermediate solutions of TXA were
prepared daily at 20000 and 1500 ngmL−1 in mobile phase, i.e. acet-
onitrile-aqueous ammonium bicarbonate (pH 7.4; 10mM) (75:25, v/v),
and further diluted in the same solvent to achieve final concentrations
of 30, 60, 90, 150, 300, 450 and 600 ngmL−1. The internal standard
(TXA-IS) was added to each TXA standard solution in order to obtain a
final concentration of 300 ngmL−1.
2.3. Sample preparation and quality control samples (QC)
Human plasma samples containing TXA (100 μL) were mixed with
acetonitrile (500 μL), containing 0.5% (v/v) of formic acid to pre-
cipitate proteins. The samples were then mixed vigorously by vor-
texing for 30 s and centrifuged at 18000×g for 6 min at 4 °C.
Supernatants were collected, TXA-IS was added at 300 ng mL−1 and,
lastly, 0.2 μL of the extract were injected into the UHPLC-MS/MS for
analysis. Whenever required, the supernatant was diluted 20× in
acetonitrile-aqueous ammonium bicarbonate (pH 7.4; 10 mM)
(75:25, v/v) before analysis. Quality control (QC) samples at three
different levels (low, medium and high) were prepared in mobile
phase and in plasma extract at concentrations of 90, 300 and
600 ng mL−1.
2.4. UHPLC-MS/MS analysis
Chromatographic analysis was performed in a Nexera X2 UHPLC
system comprising two LC-30AD pumps, a DGU-20A5R degassing unit,
a SIL-30AC autosampler and a CTO-20AC oven (Shimadzu Corporation,
Kyoto, Japan). The MS/MS system was a triple quadrupole LCMS-8040
mass spectrometer equipped with an electrospray ionization source
(ESI) (Shimadzu Corporation). The UHPLC-MS/MS system was also
equipped with an additional LC-20AD pump and a diverter valve FCV-
20AH2 (Shimadzu Corporation) that permit to divert to waste non-re-
levant portions of chromatographic runs, thus minimizing fouling of the
ESI probe and sample cone.
A BEH Amide column (50×2.1mm, 1.7 μm; Waters, Milford, MA,
USA), maintained at 40 °C, was used as stationary phase. The chroma-
tographic separation was performed in isocratic mode using as mobile
phase a mixture of acetonitrile-aqueous ammonium bicarbonate
(pH 7.4; 10mM) (75:25, v/v), at a flow rate of 0.1 mLmin−1. The total
run time was 8.0 min, with a retention time of 6.4 min for TXA. During
each chromatographic run, the column eluate was diverted to waste
from 0 to 5.5 min, directed to MS interface between 5.5 and 7.6 min and
again diverted to waste until 8.0 min.
The MS was operated in positive ionization mode (ESI+) and data
was acquired in selected reaction monitoring (SRM) mode. The product
ions monitored for TXA were m/z 158.25 > 95.15 for quantification,
and 158.25 > 123.20 for identification. 13C2,15N,trans-TXA was em-
ployed as internal standard and monitored at m/z transitions
161.25 > 96.15 and 161.25 > 125.20 with similar purposes. The
following parameters were used for analysis: nebulizing gas (N2) flow
rate at 1.5 Lmin−1, drying gas (N2) flow rate at 18.0 Lmin−1, deso-
lvation line temperature at 280 °C, heat block temperature at 400 °C,
detector voltage at 1.88 kV, collision gas (argon) at 230 kPa. The in-
jection volume was 0.2 μL. Peak detection and quantification were
performed using LabSolutions software version 5.60 SP2 (Shimadzu
Corporation).
Fig. 1. Structure of pseudo-molecular ion of tranexamic acid (TXA) and corresponding internal standard, the isotopically labeled TXA (13C2,15N-TXA).
2.5. Analytical method validation
The developed UHPLC-MS/MS method was validated for selectivity,
linearity and range, precision and accuracy, limits of detection (LOD)
and quantification (LOQ), stability, matrix effect, recovery and carry-
over effect.
2.5.1. Selectivity
The interference from endogenous components of the biological
matrices or other components in the TXA samples was investigated by
analysing six different blanks of each matrix including mobile phase
and human plasma [23].
2.5.2. Carry-over effects
The possibility of carry-over was assessed by injecting mobile phase,
i.e. acetonitrile-aqueous ammonium bicarbonate (pH 7.4; 10mM)
(75:25, v/v) following the analysis of the highest calibration standard
(600 ngmL−1) and also during sample analysis, following the analysis
of 6 consecutive samples.
2.5.3. Linearity and calibration range
To evaluate linearity and working range, calibration curves cov-
ering the expected therapeutical concentrations were prepared and
acquired in triplicate, in three independent analytical runs. Each cali-
bration curve was established by plotting the ratio analyte peak area/IS
peak area vs. the nominal concentration of TXA standard solutions
prepared in mobile phase. Seven concentration levels were used (30,
60, 90, 150, 300, 450, 600 ngmL−1), corresponding to
0.18–3.6 μgmL−1 (dilution 1:6) or to 3.6–72 μgmL−1 (dilution 1:120)
in plasma samples. Back calculated concentrations of the calibration
standards were determined as recommended by EMA guideline [23].
Furthermore, a blank sample (without analyte and without IS) and a
zero sample (only with IS) were included in each analytical run.
2.5.4. Accuracy and precision
Accuracy and precision were determined by assaying QC samples at
three concentration levels (90, 300 and 600 ngmL−1 of TXA) for mo-
bile phase and human plasma extracts (corresponding to 0.54, 1.8, and
3.6 μgmL−1 in plasma and to 10.8, 36, and 72 μgmL−1 in diluted
plasma (1:20)). The accuracy expressed by percentage of the nominal
concentration value, and precision expressed by the coefficient of var-
iation (CV), were calculated as follows: accuracy (%)= (mean mea-
sured concentration/nominal concentration)× 100; precision (CV,
%)= (standard deviation/mean)× 100. Intra-day (within-run) values
were obtained by replicate analyses (n=6) followed by interpolation
in the calibration curve established on the same day. Inter-day (be-
tween-run) values were obtained from 3 independent experiments
(n=3).
Furthermore, to evaluate if sample dilution affects the accuracy and
precision, QC samples were spiked with TXA at a concentration level
above the highest calibration standard and diluted to fall within the
calibration curve range before analytical determination. Dilution in-
tegrity was assayed by spiking 1800 ngmL−1 of TXA in mobile phase
and plasma extracts and diluting 1:20 in mobile phase before LC-MS/
MS quantification.
2.5.5. Limits of detection and quantification
Limit of detection (LOD) and limit of quantification (LOQ) values
for TXA in each matrix (n=10) were determined by the signal-to-noise
ratio, defined as the concentrations that originated a signal-to-noise
ratio of 3:1 and 10:1, respectively [24].
2.5.6. Stability
Short-term stability at room temperature (RT), freeze and thaw
stability and autosampler stability were evaluated in processed sam-
ples. The short-term stability of TXA was assessed by maintaining the
QC samples at RT (20 ± 2 °C) for 24 h. Freeze (−20 °C) and thaw
stability of the samples was obtained over three freeze-thaw cycles, by
thawing at RT for 2 h and refreezing for 24 h. Autosampler stability of
TXA was assayed by analysis of QC samples, which were stored in the
autosampler (+5 °C) of the UHPLC instrument for 24 h. For each con-
centration and each storage condition, six replicates were analysed in
the same analytical batch. The concentration of the target analyte after
the storage period was compared to the initial concentration de-
termined for the freshly prepared samples, analysed immediately after
preparation.
2.5.7. Recovery and matrix effect
The recovery of TXA from human plasma was assessed by spiking
plasma samples with TXA and IS before extraction and sample pro-
cessing, in order to achieve final concentrations of 90 and 300 ngmL−1
TXA in extracts. Sample processing was performed as described in
Section 2.3. The percentage of recovery was obtained by comparing the
peak area of spiked samples with the peak area of standard solutions
prepared at the same concentrations.
Matrix effect was assessed by the post-extraction addition method,
using six different blanks of plasma matrix. As recommended, the ma-
trix factor (MF) was calculated for TXA and corresponding IS, by
comparing the peak area obtained in spiked blank matrix extracts with
the peak area obtained for the same concentration of analyte in mobile
phase. Matrix effect was determined at two concentration levels of TXA
(90 and 300 ngmL−1), adding 300 ngmL−1 of TXA-IS in both cases.
The IS normalized MF was also determined by dividing the MF of TXA
by the MF of the corresponding TXA-IS [23].
2.6. Application to a clinical study of samples recovered during scoliosis
surgery
The study followed internationally accepted rules of good clinical
practices and was approved by the Ethics Committee for Health at
Centro Hospitalar do Porto (process no. 2015.083(077-DEFI/072-CES)).
All participating subjects have given their written informed consent.
Briefly, the patients had an initial bolus of 10mg kg−1 of TXA during
15min, 15min before surgical incision, followed by continuous infu-
sion of 1mg kg−1 h−1 from surgical incision to closure of the surgical
wound. Blood samples were collected at the end of surgery and 24 h
later for quantification of TXA. Blood samples were collected into EDTA
tubes and centrifuged at 3500 rpm. The plasma samples (supernatant)
were collected and stored at −20 °C prior to analysis. After thawing,
samples were processed as described in Section 2.3 and analysed by
UHPLC-MS/MS. QC samples were run every fifteen injections.
3. Results and discussion
Considering the method application to studies of pharmacokinetics
and pharmacodynamics, involving pediatric patients under low doses
regimen, the main goal of this work was the development of a chro-
matographic method with low detection and quantification limits, using
reduced sample volumes. Furthermore, as a high sample throughput
was aimed, a streamlined sample treatment procedure was pursued for
straightforward application to LC-MS/MS analysis.
3.1. Sample preparation
The plasma samples were initially treated according to the proce-
dure described by Delavenne et al. [19]. This sample preparation
method consisted of adding 500 μL of acetonitrile containing
500 ngmL−1 of IS to 100 μL of sample. This mixture was vortexed
during 30 s and centrifuged at 18000×g for 6min at 4 °C. A volume of
10 μL of the supernatant was injected into the LC system, using the
same column and solvent system applied in the previously described
method. This experiment produced chromatogram peaks with an
irregular shape and tailing (data not shown), which might indicate the
presence of tranexamic acid as different ionic species, along with a poor
recovery of the analyte (ca. 20%). Moreover, these conditions led to a
TXA retention time close to the void volume signal, coinciding with the
elution of non-retained matrix components, which fosters severe matrix
effects.
The TXA molecule contains two ionizable groups in its structure, a
carboxyl and an amino group (pKa 4.3 and 10.6, respectively), and is
therefore a highly polar compound that exists as a zwitterion at phy-
siological pH. Hence, the success of its extraction from sample is highly
dependent on the pH value. For instance, the predominant form at
pH 2.6 is the cationic species whereas at pH 5.5 the zwitterion will
predominate. Having this in mind, the effect of the addition of formic
acid to acetonitrile, with both acting as deproteinization agents, was
studied. The use of 0.5% (v/v) of this reagent in addition to acetonitrile
proved to be the most efficient, allowing recoveries up to 90% of
analyte and greatly enhanced the peak shape. To conclude, this simple
and straightforward sample preparation method allows the required
sensitivity for clinical studies (as can be seen in Section 3.3), avoiding
expensive and time consuming methods namely solid-phase micro-
extraction (SPME) methods [16,18,20,25] or the use of colloidal silica
in combination with trivalent cations for phospholipid removal [22].
3.2. UHPLC-MS/MS method development
The stationary phase, a BEH Amide column, was selected due to its
hydrophilic interaction based mechanism and proven efficiency in the
separation of TXA from human plasma [19]. We have first attempted
the separation of TXA using the chromatographic method developed by
Delavenne et al. [19] that considers elution with acetonitrile-water
(80:20, v/v) both containing 0.1% (v/v) formic acid, at a flow rate of
0.8 mLmin−1. In these conditions, and using the novel proposed
sample treatment procedure, the analyte was not retained in the sta-
tionary phase and was eluted with a retention time close to that of
matrix interferences. As the inefficient separation causes a reduction of
the method's sensitivity, the development of a chromatographic method
that permitted the increase of TXA retention time was pursued. As
mentioned above, the use of formic acid in the mobile phase leads to the
predominance of the cationic form of TXA while for values close to
neutral pH, the zwitterionic species form prevails. In this form, both
carboxylate and ammonium groups interact with the amide group of
the stationary phase leading to an increase of the retention time. Hence,
ammonium bicarbonate (NH4HCO3) at 10mM (pH 7.4) was tested as an
additive of the mobile phase and further studies were performed using
this compound.
Subsequently, the effect of aqueous to organic ratio and the flow
rate applied were investigated. As expected, the retention time of TXA
increased with the percentage of the organic phase. To attain a fast
separation while maintaining good separation of TXA from matrix
components eluted within the void volume, the proportion of organic to
aqueous components in the mobile phase was fixed at 75:25 (v/v). The
flow rate applied was also studied in order to maximize sample
throughput and minimize mobile phase consumption. The values for
TXA retention time were 4.8, 2.4 and 1.2min when applying flow rates
of 0.1, 0.2, and 0.4 mLmin−1, respectively. A flow rate of 0.1mLmin−1
was selected because, compared to 0.2 mLmin−1, the lowest flow rate
corresponded to an increased analytical signal in the MS detector.
Additionally, a better separation of TXA peak from non-retained matrix
components was achieved with the lowest flow rate. The subsequent
use of the diverter valve as described in Section 2.4 resulted in a TXA
retention time of 6.4min and a total run of 8.0min.
Finally, the effect of buffering species in TXA retention time was
revisited, applying the above optimized conditions, as shown in Fig. 2.
The chromatograms of human plasma samples spiked at 600 ngmL−1
of TXA in final extract, were acquired in SCAN and SRM mode using
each additive (NH4HCO3 at 10mM (pH 7.4), Fig. 2A or HCOOH 0.1%
(v/v), Fig. 2B) in the mobile phase (acetonitrile-water 75:25, v/v), at a
flow rate of 0.1mLmin−1. The use of ammonium bicarbonate increased
the retention time and allowed, unequivocally, a more efficient se-
paration of the analyte from the matrix interferences reducing, there-
fore, matrix effects and increasing method sensitivity.
Similarly to other reported MS/MS methods, the ions [M+H]+
observed in the Q1 spectrum at m/z 158.25 and 161.25 were chosen as
precursor ion of TXA and TXA-IS, respectively [14,15,17–19]. The most
sensitive mass transition observed in TXA product ion spectra, selected
for quantification, was from m/z 158.25 to 95.15. A secondary transi-
tion from m/z 158.25 to 123.20 was used for identity confirmation.
These product ions result firstly from concomitant loss of water and
ammonia (SRM1, Fig. 1) and subsequent loss of carbon monoxide
(SRM2, Fig. 1). The corresponding TXA-IS product ions observed at m/z
96.15 and 125.20 (Fig. 1) were selected as quantifying and qualifying
ion SRM transitions, respectively. Retention time, quantifying and
qualifying ion SRM transitions, as well as optimized collision energies,
are presented in Table S1.
3.3. Method validation
The selectivity of the proposed UHPLC-MS/MS method was tested in
6 different blank samples of plasma. The overlapping of chromatograms
obtained after analysis of blank matrix and from 300 ngmL−1 TXA
standard (Fig. S1) showed no interference from endogenous compounds
present in samples at TXA and TXA-IS retention time window, for the
specified ion transitions. Potential interfering compounds were washed
from the column together with the solvent front. Hence, the developed
method is selective.
Regression data analysis was performed to establish calibration
curves plotted for peak area ratio (TXA/TXA-IS) versus TXA con-
centration, for an injection volume of 0.2 μL. The calibration curves
(seven concentration points of three replicates each) exhibited good
Fig. 2. Chromatogram of plasma spiked with 600 ngmL−1 of TXA in final ex-
tract, acquired in SCAN (grey line, left y-axis) and SRM modes (black line, right
y-axis) using ammonium bicarbonate (A) or formic acid (B) as additive of the
mobile phase.
linearity and were reproducible between 30 and 600 ngmL−1 with
coefficient of correlation r2≥ 0.9974. Higher concentration values
(1000–1200 ngmL−1) were not included in the calibration curve to
avoid the introduction of large amounts of TXA in the ESI interface,
preventing contamination and loss of sensitivity for low ngmL−1.
The back calculated concentrations presented deviations within±
15% from the nominal value, meeting the requirements of EMA
guideline [23] (results not shown). Sensitivity, assessed as the slope of
the calibration curve, presented the mean value of 0.003 ng−1 mL. For
human plasma extracts, LOD and LOQ values were 3 and 6 ngmL−1,
corresponding to 18 and 36 ngmL−1 in plasma samples, respectively.
Intra- and inter-day precision and accuracy of the TXA assay were
estimated at low, medium and high QC concentrations (90, 300, and
600 ngmL−1) representative of the calibration range, as depicted in
Table 1. Both intra- and inter-day precision and accuracy exhibited
values that pass EMA requirements for bioanalytical assay validation
[23], i.e., the precision, represented as CV, did not exceed 15% and the
accuracy range was between 85 and 115%. The intra-day precision was
≤4.5% and the accuracy ranged between 96.3 and 106% of the nom-
inal TXA concentrations. The inter-day precision was ≤7.0% and the
accuracy ranged between 94.7 and 104% (Table 1). Furthermore, di-
lution of samples did not affect the method accuracy and precision, as
both parameters were maintained within the set criteria (± 15%).
TXA was stable in mobile phase and plasma extracts in all tested
conditions as the calculated mean concentrations were within± 15% of
the nominal concentration [23] (Table 2). Short-term stability assessed
after 24 h at room temperature (RT) and after 24 h in the autosampler
at 5 °C did not show analyte degradation. Accuracy ranges of
88.0–105% and 99.7–109%, with mean values of 94.7 ± 7.7% and
104.0 ± 3.9%, were determined in these conditions (Table 2). TXA
was also found stable in mobile phase and plasma extracts after three
freeze-thaw cycles, with accuracy values ranging between 98.5 and
106% and a mean value of 102.3 ± 3.1% (Table 2).
The recovery of TXA from plasma samples was evaluated at two QC
concentration levels (90 and 300 ngmL−1, two replicates each), by spiking
plasma harvested from healthy volunteers with TXA and IS before sample
processing as described in Section 2.3 (Table 3). Recovery assays of TXA
were repeatable (CV≤ 6.2%) with mean recovery values of 94.1 ± 3.1%
whereas for the internal standard (TXA-IS) mean recovery values of
92.6 ± 2.5% with CV≤ 5.3% were attained, proving the method suit-
ability for reliable bioanalysis. Moreover, for current process of samples,
addition of IS is not required before extraction as recovery values are
within recommended levels (≥85%).
The matrix effect of plasma components on the analysis of TXA was
evaluated as the percentage ratio between the peak area obtained for
post-spiked matrix extracts and the peak area obtained for a standard
solution with the same analyte concentration. No significant matrix
effect was observed for TXA and corresponding TXA-IS in plasma
samples, with mean matrix factor (MF) values of 100.7–110.0%
(Table 4). The application of IS compensated the impact of matrix in-
terferences with IS-normalized MF values of 100.9 and 100.0% for TXA
concentrations of 90 and 300 ngmL−1, respectively. Moreover, the CV
of the IS-normalized MF calculated from the 6 lots of matrix for each
concentration was within the acceptance criteria (± 15%) [23].
Therefore, there is no need to establish calibration curves in plasma as
recommended by previously reported methods. This feature of the
proposed method allows higher sensitivity and decreases the need of
maintenance of MS/MS detector.
In summary, the proposed method employs a simple and straight-
forward sample preparation method, compared to expensive and time-
consuming solid phase extraction method or phospholipid removal
[16,18,20,22]. Moreover, other previously reported methods based on
MS did not use internal standard [16,20] or monitored a single tran-
sition [14,16,20,25]. The use of ammonium bicarbonate as an additive
Table 1
Accuracy and precision for the analysis of TXA in acetonitrile-aqueous ammonium bicarbonate (pH 7.4; 10mM) (75:25, v/v) and human plasma extracts.
Matrix Nominal concentration (ngmL−1) Intra-day Inter-day













Mobile phase 90 95.1 106 4.5 93.9 104 7.0
300 292 97.3 2.1 286 95.3 2.0
600 603 101 2.4 589 98.2 2.6
Plasma 90 94.2 105 4.0 93.0 103 6.8
300 289 96.3 1.7 284 94.7 1.7
600 602 100 2.2 586 97.7 2.8
Table 2
Stability of TXA in different matrices stored at different experimental conditions.
Matrix Nominal concentration (ngmL−1) Measured concentration
(24 h at room temperature)
Measured concentrations





















Mobile phase 90 94.8 105 1.7 96.6 107 1.9 91.4 102 4.7
300 270 90.0 3.4 304 101 2.6 297 99.0 1.6
600 554 92.3 1.9 606 101 1.9 629 105 2.8
Plasma 90 93.9 104 3.1 98.2 109 4.8 88.6 98.5 2.6
300 264 88.0 1.6 299 99.7 1.9 308 103 4.3
600 533 88.8 3.5 635 106 1.5 634 106 2.4
Table 3
Recovery of TXA and corresponding internal standard from plasma samples.
TXA concentration
(ngmL−1)
Recovery (TXA) Recovery (IS)
Mean (%) CV (%) Mean (%) CV (%)
540 91.9 6.2 90.9 5.3
1800 96.3 3.6 94.4 1.0
TXA, tranexamic acid; IS, internal standard.
of the mobile phase allowed the quantification of TXA in 6.4 min, with a
total run time of 8min. Other proposed methods attained shorter or
equal runs granting, although, LOD/LOQ values higher to those ob-
tained in the present work (40–380 ngmL−1 and 10–760 ngmL−1)
[17–19]. The lowest LOD and LOQ values (10 and 20 ngmL−1) re-
ported before in the literature were attained for TXA extracted from
200 μL of plasma, a volume 2-fold higher than the one applied in this
work [14]. For methods using fluorimetric or UV–Vis detection for
quantification of TXA in human plasma samples, higher LOD and LOQ
were obtained [6]. Hence, the proposed method has an excellent sen-
sitivity with an LOQ of 6 ngmL−1 in plasma extracts (36 ngmL−1 in
plasma) that corresponds to 1.2 pg on column, which is 6- to 100-fold
lower than the values reported previously [15,16,18–20,25], except for
the method reported by Chang et al. [14]. Clinical samples with high
concentrations of tranexamic acid can be measured using this method
because the upper limit of quantification covers values up to
600 ngmL−1 minimizing the need for sample dilution and improving,
therefore, method throughput. Nevertheless, if required, dilution does
not affect method precision and accuracy as proven by dilution in-
tegrity assays.
3.4. Application to clinical samples recovered during scoliosis surgery
The developed and validated UHPLC-MS/MS method was applied to
evaluate TXA concentration at the end and 24 h after the surgery. The
values for TXA determination in plasma samples are presented in
Table 5, along with chromatograms of a blank and a sample containing
low level of TXA (Fig. 3). For confirmatory analysis of TXA in samples, a
strategy based on 4 identification points was implemented, including
one precursor and two product ions [26]. Moreover, to avoid possible
interferences and false positives, especially at low level samples, the
relative abundance of qualifying (q) to quantifying (Q) ions was mon-
itored. Values of 14.4 ± 0.5% were obtained for TXA standards (Table
S2) and chromatograms depicting both transitions for TXA at
30 ngmL−1 and for plasma extract are depicted in Fig. S2. The accep-
tance criteria used for samples was±30% as the q/Q value was in the
range 10–20% [26,27]. As shown in Table S3, values were within the
acceptance range for all tested samples, including the low level sample
depicted in Fig. S2 (%q/Q=15.1%).
Finally, TXA concentration at the end of surgery ranged from
10.0–17.1 μgmL−1 and from 219 to 332 ngmL−1 24 h after the sur-
gery, representing a decrease of about 65× in plasmatic concentration.
Nevertheless, further correlation of low ngmL−1 levels of TXA with
postoperative haemorrhage are under investigation through data ob-
tained using the proposed quantification method.
4. Conclusions
An UHPLC method coupled with tandem mass spectrometry detec-
tion was developed and fully validated for quantification of tranexamic
acid in human plasma samples. Separation was achieved using a hy-
drophilic interaction based stationary phase and ammonium bicarbo-
nate in the mobile phase that permitted a more efficient separation of
the analyte from the matrix interferences thus reducing matrix effects
and increasing method sensitivity. A simple, inexpensive and efficient
sample treatment involving protein precipitation with acetonitrile
containing 0.5% (v/v) formic acid was implemented using reduced
sample volumes. The combination of suitable sample treatment, correct
pH adjustment, and efficient chromatographic separation allowed ma-
trix-free calibration. This is an extremely advantageous feature, con-
sidering the limited availability of human plasma matrix and the high
maintenance cost of MS/MS detector.
The developed UHPLC-MS/MS method proved to be sensitive, selec-
tive, accurate and precise for the quantitative analysis of tranexamic acid
in human plasma samples, in a wide concentration range. High and con-
sistent recovery values were obtained and potential matrix effects were
balanced by the application of an isotopically labeled internal standard.
LOD and LOQ values in the ng mL−1 level were attained, being compar-
able or even lower than values previously reported in the literature.
Moreover, these features could be improved for lower level samples by
increasing the injection volume (e.g. 2 μL). The proposed method was
found to be suitable for determination of TXA in real plasma samples
collected from pediatric patients undergoing scoliosis surgery.
Table 4












Mean (%) CV (%) Mean (%) CV (%)
90 101.6 2.5 100.7 1.4 100.9 1.6
300 110.0 7.6 110.0 6.3 100.0 1.4
TXA, tranexamic acid; IS, internal standard.
a IS at constant concentration of 300 ngmL−1.
b IS normalized matrix factor calculated by division of the matrix factor of
the analyte by the matrix factor of the IS.
Table 5
Quantification of TXA in plasma samples collected from pediatric patients un-
dergoing idiopathic scoliosis surgery.
Plasma samples TXA concentrationa
End of surgery (μgmL−1) 24 h after surgery (ngmL−1)
Patient 1 11.2 ± 0.1 219 ± 2
Patient 2 16.0 ± 0.1 229 ± 1
Patient 3 17.1 ± 0.2 332 ± 2
Patient 4 14.2 ± 0.1 226 ± 6
Patient 5 10.0 ± 0.1 275 ± 1
a Each value corresponds to the mean ± standard deviation (n=2). Prior to
analysis by UHPLC-MS/MS, samples extracts collected at the end of surgery
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Fig. 3. Overlaid chromatograms of a low concentration plasma sample
(24.5 ngmL−1 TXA in final extract) from pharmacokinetic study (black line)
and a blank plasma extract (grey line), with zoom insert on TXA retention time
window (6.4min).
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